Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties (Q34232063)

31 July 2017

1 reference

title

Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties (English)

1 reference

31 July 2017

Lehtonen LA

1

1 reference

PubMed ID

11322869

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

5

1 reference

31 July 2017

955-970

1 reference

Classification of positive inotropic agents

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Drug binding to cardiac troponin C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Levosimendan improves diastolic and systolic function in failing human myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Myocardial efficiency during levosimendan infusion in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

21 January 2018

Heart failure update.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.955

10.1517/13543784.10.5.955

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11322869